Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mobiles apps

- PMLiVE

Novo Nordisk gets FDA nod for once-weekly rival to Lilly’s Trulicity

GLP-1 agonist Ozempic approved in the US for type 2 diabetes

FDA approves first substance use mobile medical application

Pear Therapeutics' Reset device offers cognitive behavioural therapy

- PMLiVE

Sanofi looks to mobile data to power behavioural analysis

Teams up with Evidation Health for a new digital health partnership

- PMLiVE

Shire to customise MicroHealth’s app for haemphilia patients

Will collaborate with the digital health firm on its mobile monitoring tool

- PMLiVE

Novartis trial marks ResearchKit first in MS

ElevateMS study will allow participants to contribute from smartphones

- PMLiVE

Novo’s semaglutide beats Lilly’s Trulicity in diabetes contest

Analysts predict the drug could be worth $8.7bn in the next five years

- PMLiVE

Novo Nordisk bolsters management team

Appoints Camilla Sylvest and Doug Langa

Sanofi: Wearables are a core part of our digital trials strategy

Pharma firm partners with Parexel on patient sensor work

- PMLiVE

Novo launches personalised diabetes management mobile app

Partners with Glooko on app that syncs blood glucose and activity data

- PMLiVE

Dr Bug mobile game introduces kids to antibiotics, bacteria and viruses

The not-for-profit app is a collaboration between Oxford PharmaGenesis and Global Initiative

Shift to value-based medicine will boost mHealth uptake

Advances in devices and network coverage will also both contribute, say analysts

- PMLiVE

FDA panel backs CV claims for Novo Nordisk’s Victoza

LEADER trial shows the diabetes treatment reduces risk of cardiovascular death by 13%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links